Perspective Therapeutics (CATX) Equity Income (2023 - 2026)

Perspective Therapeutics has disclosed Equity Income across 4 years of filings, most recently posting -$1000.0 for Q2 2026.

• In Q2 2026, Equity Income changed N/A year-over-year to -$1000.0; the TTM figure through Jun 2026 stood at -$2000.0 (up 33.33% YoY), while the FY2025 annual figure was -$2000.0, up 75.0% from the prior year.
• Equity Income came in at -$1000.0 for Q2 2026 at Perspective Therapeutics, roughly flat from -$1000.0 in the prior quarter.
• In the past five years, Equity Income ranged from a high of -$1000.0 in Q1 2025 to a low of -$12000.0 in Q3 2023.
• Average Equity Income over 4 years is -$3857.1, with a median of -$2000.0 recorded in 2024.
• Year-over-year, Equity Income jumped 60.0% in 2024 and surged 50.0% in 2025.
• Over 4 years, Equity Income stood at -$5000.0 in 2023, then jumped by 60.0% to -$2000.0 in 2024, then surged by 50.0% to -$1000.0 in 2025, then changed by 0.0% to -$1000.0 in 2026.
• Per Business Quant data, the three most recent Equity Income figures were -$1000.0 in Q2 2026, -$1000.0 in Q1 2025, and -$2000.0 in Q4 2024.